Press-release for stocks for MRTX

Prices are updated after-hours

symbols : MRTX

save search

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 73.97% | O: -14.97% H: 11.97% C: 8.9%
lung review update cancer cell treatment therapeutics

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
Published: 2023-06-23 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
therapeutics

Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
Published: 2023-06-20 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 56.98% | O: -1.15% H: 0.16% C: -1.94%
krasg12 treatment system results

Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
Published: 2023-06-01 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 58.29% | O: -0.89% H: 1.36% C: 0.49%
conference global therapeutics

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Published: 2023-05-30 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 58.54% | O: 0.43% H: 2.55% C: -0.27%
krasg12 asco tumors treatment meeting potential

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $48.3 0.96% 0.33% 8.9M

Health Technology

| -26.23% | O: -0.81% H: 0.32% C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 34.17% | O: -6.18% H: 0.0% C: -6.64%
opdivo update sapphire therapeutics study

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 12.48% | O: -0.21% H: 0.32% C: -0.07%
ZLAB | News | $14.2 3.5% 3.38% 690K

Health Technology

| -61.68% | O: 4.89% H: 6.5% C: 1.13%
SGEN | $228.74 0.1% 20M

Health Technology

| 14.37% | O: 0.17% H: 0.07% C: -0.17%
NVCR | $12.04 -0.08% -0.08% 1.4M

Health Technology

| -82.79% | O: 1.11% H: 1.89% C: 0.97%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 24.33% | O: -2.41% H: 5.41% C: 3.75%
KRTX | $329.83 0.0% 1.9M

Health Technology

| 51.29% | O: 1.07% H: 1.21% C: 0.62%
INCY | $52.82 0.19% 0.19% 1.8M

Health Technology

| -18.45% | O: 0.29% H: 0.07% C: -1.6%
BPMC | News | $88.9 0.59% 0.58% 730K

Health Technology

| 62.12% | O: 1.36% H: 0.13% C: -1.89%
results

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-05-05 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
nasdaq grant therapeutics

Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 36.5% | O: 1.44% H: 0.66% C: -0.21%
america conference health care therapeutics

Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Published: 2023-04-26 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 36.5% | O: 1.44% H: 0.66% C: -0.21%
krasg12 rapid tumors treatment communication

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
Published: 2023-04-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 36.0% | O: -0.67% H: 1.16% C: 0.3%
therapeutics report financial results

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Published: 2023-04-03 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 52.11% | O: 0.85% H: 0.21% C: -4.26%
research

Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
Published: 2023-03-06 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 41.43% | O: 0.05% H: 2.48% C: 0.41%
global conference therapeutics

Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
Published: 2023-02-21 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 29.7% | O: 1.1% H: 1.12% C: 0.39%
care conference health therapeutics

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023
Published: 2023-02-14 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 21.33% | O: -1.11% H: 2.41% C: 1.61%
report year therapeutics financial

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-02-03 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| Email alert Add to watchlist
nasdaq grant therapeutics

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
Published: 2023-02-01 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| 11.63% | O: 1.84% H: 2.77% C: 1.12%
therapeutics